Atlas Trials

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

Clinical trial NCT04405739 · COMPLETED

Trial details

NCT number
NCT04405739
Sponsor
Ridgeback Biotherapeutics, LP
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
SARS-CoV 2
Start date
2020-06-16
Primary completion
2022-02-21
Enrollment
71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.